The immunomodulatory/immunosuppressive classification system

Moderate-to-Severe Psoriasis, Third Edition

Volumn , Issue , 2008, Pages 365-377

  Koo, John Y M ^a   Behnam, Shahrad M ^b,c   Behnam, Shahdad E ^d   Bae, Dana ^e   Tuerk, Melanie J ^f   Bernal, Myriam ^g   Dubois, Robert W ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CERNER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883825729     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (33)

1. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
2. Callen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003; 49: 897-899.
3. Lebwohl M, Ali S. Treatment of psoriasi. Part 2. Systemic therapies. J Am Acad Dermatol 2001; 45: 649-661.
4. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137 41 41:280-284.
5. Hoog R, Tanis E. Probability and Statistical Inference, 4th ed. New York, NY: Macmillan, 1993.
6. Merck & Co, Inc. VIOXX® (rofecoxib tablets and oral suspension) [package insert]. http://www.fda.gov/cder/foi/label/1999/21042lbl.pdf. Accessed August 27, 2004.
7. Pharmacia and Pfizer. Celebrex (celecoxib capsules). http://www.celebrex.com/pdf/Celebrex PI.pdf. Accessed August 27, 2004.
8. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206 41:37-53.
9. Jain A, Sangal L, Basal E. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. http://dermatology.cdlib.org/DOJvol8num2/. Accessed August 27, 2004.
10. American Osteopathic College of Dermatology. Minocycline. Dermatologic disease database at: http://www.aocd.org/skin/dermatologic diseases/minocycline.html. Accessed August 24, 2004.
11. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J Invest Dermatol 2003; 120: 211-216.
12. Penn I. Post-transplant malignancy: The role of immunosuppression. Drug Saf 2000; 23: 101-113.
13. Nelson RP Jr, Ballow M. 26. Immunomodulation and immunotherapy: Drugs, cytokines, cytokine receptors, and antibodies. J Allergy Clin Immunol 2003; 111: S720-S743.
14. Penn I. Overviewof the problem of cancer in organ transplant recipients. Ann Transplant 1997; 2:5-6.
15. Dauno Xome (daunorubicin citrate) [package insert]. http://www.icon.co.za/~key/daunoxome/pres/prescribinginfo.htm. Accessed August 27, 2004.
16. Pharmacia, Inc. Adriamycin (doxorubicin hydrochloride) [package insert]. http://www.meds.com/leukemia/idamycin/adriamycin.html. Accessed August 27, 2004.
17. Astra Zeneca. Pulmicort (budesonide inhalation suspension) package insert. http://www.astrazeneca-us.com/cgibin/azpi.asp?product=pulmicort resp. Accessed August 27, 2004.
18. Aithal GP, Haugk B, Das S, et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: Are serial liver biopsies justified? Aliment Pharmacol Ther 2004; 19: 391-399.
19. Polo Romero FJ, Blasco Colmenarejo MM, Tirado MR, et al. Advanced liver fibrosis secondary to methotrexate treatment. Gastroenterol Hepatol 2003; 26: 617-618.
20. Fujisawa Healthcare, Inc. Protopic (tacrolimus) [package insert]. http://www.fda.gov/cder/foi/label/2000/50777lbl.pdf. Accessed August 27, 2004.
21. Fung JJ. Tacrolimus and transplantation: A decade in review. Transplantation 2004; 77: S41-S43.
22. Schosser R. Risk/benefit evaluation of drugs: The role of the pharmaceutical industry in Germany. Eur Surg Res 2002; 34: 203-207. Available at: http://www.baxter.de/presseforum/downloads/Baxter Sonderdruck Eur Surg Res.pdf. Accessed September 2, 2004.
23. Sparing R, Sellhaus B, Noth J, et al. Rhabdomyolysis following cerivastatin monotherapy-implications for therapy with HMG-CoA reductase inhibitors. Nervenarzt 2003; 74: 167-171.
24. Lee WM. Drug-induced hepatotoxicity N Engl J Med 2003; 349:474-485.
25. Centocor Corporation. Remicade (infliximab) FDA Arthritis Advisory Committee Briefing Document. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm. Accessed August 27, 2004.
26. U.S. Food and Drug Administration. Safety concerns associated with over-thecounter drug products containing analgesic/antipyretic active ingredients for internal use. http://www.fda.gov/cder/drug/analgesics/SciencePaper.pdf. Accessed August 27, 2004.
27. American Academy of Dermatology Association. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol 1996; 35: 615-619.
28. Sarkar R, Kanwar A. Atopic dermatitis. Indian Pediatr 2002; 39: 922-930.
29. Krafchic B. Atopic dermatitis. http://www.emedicine. com/derm/topic38.htm. Accessed August 27, 2004.
30. Immunex Corp and Amgen Corp. Enbrel (etanercept) [package insert]. www.fda.gov/cder/foi/label/2003/etanimm060503LB.pdf. Accessed August 27, 2004.
31. Russell J. Topical tacrolimus: A new therapy for atopic dermatitis. Am Fam Physician 2002; 66: 1899-1902.
32. Koo J, Kochavi G, Kwan J. Contemporary Diagnosis and Management of Psoriasis, 1st ed. PA: Handbooks in Health Care Co. Newtown, Pennsylvania, USA, 2004, pp. 45-51.
33. Kurki PT. Safety aspects of the long term cyclosporin A therapy. Scand J Rheumatol Suppl 1992; 95: 35-38.